Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

284
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
284
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

384
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
384
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

341
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
341
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.5K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.5K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

455
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
455
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

400
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
400

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and acceptability of smartphone technology for patients to self-record vital signs in the emergency department (The FacED Study): A study protocol.

PloS one·2026
Same author

Histotripsy for Liver Tumor Ablation and Beyond: <i>AJR</i> Expert Panel Narrative Review.

AJR. American journal of roentgenology·2026
Same author

Convergent Hybrid Ablation Versus Catheter Ablation in Patients With Persistent Atrial Fibrillation and Heart Failure: HALT AF Study Protocol and Rationale for a Multicenter Randomized Controlled Trial.

Journal of the American Heart Association·2026
Same author

Alignment Between Cardiologists and AI-Driven Diagnostic Systems: Mixed Methods Study.

Journal of medical Internet research·2026
Same author

Partial restoration of counterregulatory circulating glucagon by dapagliflozin and low-dose glibenclamide in men with type 1 diabetes: in vitro studies and randomised clinical crossover trial.

EBioMedicine·2026
Same author

Factors Associated With Pain Related to Insertion of a Contraceptive Intrauterine Device: Findings of a National Survey.

The Australian & New Zealand journal of obstetrics & gynaecology·2026

Related Experiment Video

Updated: Apr 3, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.8K

Vancomycin Pharmacokinetics in Obese Patients: Insights from Bayesian Modeling.

Fawzy Elbarbry1,2, Tyler Thilavanh3, Sarah White3

  • 1School of Pharmacy, Pacific University, 222 SE 8th Ave., Hillsboro, OR, 97123, USA. Fawzy.elbarbry@pacificu.edu.

European Journal of Drug Metabolism and Pharmacokinetics
|April 2, 2026
PubMed
Summary

Optimal vancomycin dosing for obese patients is challenging. Bayesian analysis shows obesity alters drug clearance and distribution, but target exposure is still achievable. Trough levels are unreliable predictors in obese individuals.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.4K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K

Related Experiment Videos

Last Updated: Apr 3, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.8K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.4K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Obesity Medicine

Background:

  • Vancomycin dosing in obese patients presents pharmacokinetic challenges.
  • Achieving therapeutic vancomycin exposure is difficult due to altered drug handling.
  • The relationship between vancomycin trough concentrations and efficacy in obesity is variable.

Purpose of the Study:

  • To evaluate vancomycin pharmacokinetics in obese patients.
  • To assess the attainment of therapeutic vancomycin targets using Bayesian software.
  • To compare vancomycin exposure across different body mass index (BMI) categories.

Main Methods:

  • Retrospective cohort study of adult inpatients receiving intravenous vancomycin.
  • Exclusion of patients on renal replacement therapy, with AKI, pregnant, or on ECMO.
  • Bayesian pharmacokinetic analysis using PrecisePK software, categorizing patients by BMI.

Main Results:

  • Mean vancomycin clearance and volume of distribution increased with BMI.
  • Therapeutic AUC0-24 values were achieved in approximately half of patients across all BMI groups.
  • Trough concentrations were higher in obese patients but showed moderate correlation with AUC, with greater variability.

Conclusions:

  • Obesity significantly alters vancomycin clearance and distribution.
  • Target AUC0-24 values are achievable in obese patients, irrespective of BMI.
  • Vancomycin trough concentrations are unreliable for predicting exposure in obese patients, necessitating AUC-guided Bayesian dosing.